Skip to main content
Top
Published in: Endocrine Pathology 4/2015

01-12-2015

Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid

Authors: Guo-Xia Tong, Kokila Mody, Zhuo Wang, Diane Hamele-Bena, Marina N. Nikiforova, Yuri E. Nikiforov

Published in: Endocrine Pathology | Issue 4/2015

Login to get access

Abstract

Clear cell follicular carcinoma is a rare type of thyroid cancer and some with aggressive biological behavior. The cytoplasmic clearing of the neoplastic cells has been attributed to the accumulation of various substances, such as glycogen, lipid, mucin, and thyroglobulin, or distension of mitochondria or endoplasmic reticulum. However, the molecular mechanisms responsible for the characteristic appearance of the cell cytoplasm and the biological behavior remain unknown. We report here a case of aggressive clear cell follicular carcinoma of the thyroid with molecular profile using targeted next generation sequencing (NGS) that presented as a metastatic tumor in a woman with a history of breast carcinoma. The NGS data revealed the coexisting of a well-characterized loss-of-function TP53 R248Q mutation and a putative gain-of-function mutation of TSHR L272V, which was suggested by the overexpression of thyroglobulin and SLC5A5 (NIS) genes in this tumor. TP53 mutations are usually related with dedifferentiation, progression, and metastasis of thyroid carcinomas. Identification of TP53 R248Q in this tumor correlated with its aggressive clinical behavior. Gain-of-function mutation of TSHR can overstimulate the thyroid follicular cells as the elevated level of TSH does and might have contributed to the development of clear cell morphology in this tumor. This report represents the first case of clear cell follicular carcinoma of the thyroid with NGS analysis and more molecular characterization is needed to elucidate the pathogenesis and provide more prognosis-relevant information for this uncommon variant of thyroid carcinomas.
Literature
1.
go back to reference Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 1985;9:705–22.CrossRefPubMed Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol 1985;9:705–22.CrossRefPubMed
2.
go back to reference Civantos F, Albores-Saavedra J, Nadji M, Morales AR. Clear cell variant of thyroid carcinoma. Am J Surg Pathol 1984;8:187–92.CrossRefPubMed Civantos F, Albores-Saavedra J, Nadji M, Morales AR. Clear cell variant of thyroid carcinoma. Am J Surg Pathol 1984;8:187–92.CrossRefPubMed
3.
go back to reference Schroder S, Bocker W. Clear-cell carcinomas of thyroid gland: a clinicopathological study of 13 cases. Histopathology 1986;10:75–89.CrossRefPubMed Schroder S, Bocker W. Clear-cell carcinomas of thyroid gland: a clinicopathological study of 13 cases. Histopathology 1986;10:75–89.CrossRefPubMed
4.
go back to reference Ropp BG, Solomides C, Palazzo J, Bibbo M. Follicular carcinoma of the thyroid with extensive clear-cell differentiation: a potential diagnostic pitfall. Diagn Cytopathol 2000;23:222–3.CrossRefPubMed Ropp BG, Solomides C, Palazzo J, Bibbo M. Follicular carcinoma of the thyroid with extensive clear-cell differentiation: a potential diagnostic pitfall. Diagn Cytopathol 2000;23:222–3.CrossRefPubMed
5.
go back to reference Andrews GA, Kniseley RM. Transformation of thyroidal carcinoma to clear-cell type. Am J Clin Pathol 1956;26:1427–38.PubMed Andrews GA, Kniseley RM. Transformation of thyroidal carcinoma to clear-cell type. Am J Clin Pathol 1956;26:1427–38.PubMed
6.
go back to reference Jayaram G. Cytology of clear cell carcinoma of the thyroid. Acta Cytol 1989;33:135–6.PubMed Jayaram G. Cytology of clear cell carcinoma of the thyroid. Acta Cytol 1989;33:135–6.PubMed
7.
go back to reference Woolner LB, Beahrs OH, Black BM, Mc CW, Keating FR, Jr. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961;102:354–87.CrossRefPubMed Woolner LB, Beahrs OH, Black BM, Mc CW, Keating FR, Jr. Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg 1961;102:354–87.CrossRefPubMed
8.
go back to reference Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627–34.CrossRefPubMed Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014;120:3627–34.CrossRefPubMed
9.
go back to reference Peter I, Besznyak I, Szanto J, et al. Clear cell thyroid cancer—undifferentiated type—an immunohistochemical and electron microscopical study. Arch Geschwulstforsch 1989;59:121–8.PubMed Peter I, Besznyak I, Szanto J, et al. Clear cell thyroid cancer—undifferentiated type—an immunohistochemical and electron microscopical study. Arch Geschwulstforsch 1989;59:121–8.PubMed
10.
go back to reference Koike A, Naruse T, Kanemitsu T, et al. Clear cell carcinoma of the thyroid. A case report. Jpn J Surg 1989;19:237–40.CrossRefPubMed Koike A, Naruse T, Kanemitsu T, et al. Clear cell carcinoma of the thyroid. A case report. Jpn J Surg 1989;19:237–40.CrossRefPubMed
11.
go back to reference Harach HR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 1988;13:43–54.CrossRefPubMed Harach HR, Franssila KO. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 1988;13:43–54.CrossRefPubMed
12.
go back to reference Dayal Y, Ucci AA, Safaii H, Pohl D. Thyroglobulin and clear-cell tumors. Am J Surg Pathol 1986;10:70–2.CrossRefPubMed Dayal Y, Ucci AA, Safaii H, Pohl D. Thyroglobulin and clear-cell tumors. Am J Surg Pathol 1986;10:70–2.CrossRefPubMed
13.
go back to reference Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol 2011;35:757–61.PubMedCentralCrossRefPubMed Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol 2011;35:757–61.PubMedCentralCrossRefPubMed
14.
go back to reference Diaz-Arias AA, Bickel JT, Loy TS, et al. Follicular carcinoma with clear cell change arising in lingual thyroid. Oral Surg Oral Med Oral Pathol 1992;74:206–11.CrossRefPubMed Diaz-Arias AA, Bickel JT, Loy TS, et al. Follicular carcinoma with clear cell change arising in lingual thyroid. Oral Surg Oral Med Oral Pathol 1992;74:206–11.CrossRefPubMed
15.
go back to reference Cassio A, Nicoletti A, Rizzello A, et al. Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatment. J Clin Res Pediatr Endocrinol 2013;5 Suppl 1:29–39.PubMedCentralPubMed Cassio A, Nicoletti A, Rizzello A, et al. Current loss-of-function mutations in the thyrotropin receptor gene: when to investigate, clinical effects, and treatment. J Clin Res Pediatr Endocrinol 2013;5 Suppl 1:29–39.PubMedCentralPubMed
16.
go back to reference Kleinau G, Biebermann H. Constitutive activities in the thyrotropin receptor: regulation and significance. Adv Pharmacol 2014;70:81–119.CrossRefPubMed Kleinau G, Biebermann H. Constitutive activities in the thyrotropin receptor: regulation and significance. Adv Pharmacol 2014;70:81–119.CrossRefPubMed
17.
go back to reference Latif R, Ali MR, Ma R, et al. New small molecule agonists to the thyrotropin receptor. Thyroid 2015;25:51–62.CrossRefPubMed Latif R, Ali MR, Ma R, et al. New small molecule agonists to the thyrotropin receptor. Thyroid 2015;25:51–62.CrossRefPubMed
18.
go back to reference Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001;14:289–96.CrossRefPubMed Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol 2001;14:289–96.CrossRefPubMed
19.
go back to reference Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–90.
20.
go back to reference Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:955–69.PubMedCentralCrossRefPubMed Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:955–69.PubMedCentralCrossRefPubMed
23.
go back to reference Yoshikawa K, Hamada J, Tada M, et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res 2010;31:401–11.CrossRefPubMed Yoshikawa K, Hamada J, Tada M, et al. Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells. Biomed Res 2010;31:401–11.CrossRefPubMed
24.
go back to reference Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 2001;72:155–63.CrossRefPubMed Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 2001;72:155–63.CrossRefPubMed
25.
go back to reference Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753–60.PubMedCentralCrossRefPubMed Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753–60.PubMedCentralCrossRefPubMed
26.
go back to reference Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–84.PubMedCentralCrossRefPubMed Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179–84.PubMedCentralCrossRefPubMed
27.
go back to reference Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369–71.PubMed Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369–71.PubMed
Metadata
Title
Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid
Authors
Guo-Xia Tong
Kokila Mody
Zhuo Wang
Diane Hamele-Bena
Marina N. Nikiforova
Yuri E. Nikiforov
Publication date
01-12-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9388-1

Other articles of this Issue 4/2015

Endocrine Pathology 4/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.